Basal cell carcinoma (BCC) is a cutaneous malignancy with a tendency to spread locally and with several clinical and histological subsets. We studied 34 patients with a clinical diagnosis of recurrent BCC on different anatomical locations, to whom imiquimod 5% cream was administered on a low-frequency regime (3 times a week for 6 weeks), with a minimum of 3 years follow-up after completion of treatment. Clinical clearance rate at 1, 2 and 3 years were 94, 76 and 70%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1684/ejd.2009.0741 | DOI Listing |
Acta Pharmacol Sin
January 2025
School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Psoriasis is a chronic, systemic immune-mediated skin disease. Although many new strategies for psoriasis treatment have been developed, there is great need in clinic for treating psoriasis. Gentiopicroside (GPS), derived from Gentiana manshurica Kitagawa, has multiple pharmacological activities including anti-inflammatory, anti-oxidative and antiviral activities.
View Article and Find Full Text PDFJ Prosthodont Res
January 2025
Division of Bio-prosthodontics, Department of Oral Health Science, Niigata University Graduate School of Medical and Dental Sciences, Gakkocho-dori, Chuo-ku, Niigata Japan.
Purpose: Psoriasis is a complex, chronic inflammatory keratosis of unclear origin that is challenging to treat. In patients with psoriasis suspected of having metal allergies, the removal of oral metallic prostheses contributes to the alleviation of psoriasis symptoms. However, the relationship and mechanism of the metal removal effect and improvement in psoriasis symptoms in patients with metal allergies are unknown.
View Article and Find Full Text PDFOral Surg Oral Med Oral Pathol Oral Radiol
December 2024
Oral Medicine Division, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre-RS, Brazil. Electronic address:
Objective: actinic cheilitis (AC) is a potentially malignant disorder of the lip vermillion. The study of effective therapeutic options is of the utmost importance to prevent the development of lip squamous cell carcinoma. This study aimed to evaluate the topical effect of imiquimod 5% (IM) and fludroxycortide (FC) 0.
View Article and Find Full Text PDFDermatol Reports
November 2024
Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.
Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. Severe systemic side effects associated with imiquimod 5% cream are rare, although a few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated with topical treatment with imiquimod of two superficial basal cell carcinomas.
View Article and Find Full Text PDFEur Urol Open Sci
January 2025
Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Introduction And Objective: Imiquimod (IQ) is an immunomodulator used in the management of penile intraepithelial neoplasia (PeIN) lesions. However, IQ treatment may be associated with bothersome side effects (SEs). To date, studies reporting on this morbidity and evaluating predictors of response to IQ are scarce and included small cohorts.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!